Money & Care

The Cruel Math of the New Alzheimer's 'Miracle' Drugs

Leqembi and Kisunla promise to buy time, but the financial and physical toll of these infusions might cost you more than you ever get back.

By Neil D'Monte, Palmelle Editorial Team · Reviewed by Neil D'Monte · 7 min read · 2026-06-24

Every few months, a headline breaks about a new drug that promises to claw back pieces of a fading mind. The latest entries, Leqembi and Kisunla, arrived with breathless press releases and soaring stock prices. But if you look past the optimism of drug developers, these treatments merely stretch out the early stages of cognitive decline by a few months at a staggering cost.

SHORT ANSWER

These drugs buy about five months of slower decline at a real-world cost of $10,000+ out-of-pocket annually, while introducing risks of brain swelling and bleeding.

The direct answer

The new antibody treatments for Alzheimer's cost between $26,500 and $32,000 annually for the medication alone. When you add mandatory PET scans, bi-weekly infusions, and regular MRIs to monitor for brain bleeding, the real cost pushes past $90,000 a year. Medicare covers 80% of the drug cost if your doctor participates in a registry, leaving you with at least $5,300 to $6,400 in annual out-of-pocket drug costs, plus thousands more for diagnostic imaging.

The High Price of Five Extra Months

Let us look at the actual benefit of Leqembi. In its primary trial, the drug slowed cognitive decline by 27% over an 18-month period. In plain English, that translates to about five months of preserved cognitive function.

To get those five months, your parent must travel to an infusion center every two weeks. They will sit hooked to an IV for an hour, twice a month, indefinitely. This is not a pill you take at breakfast; it is a part-time job for the family caregiver.

The list price for Leqembi is $26,500 per year. Kisunla, approved more recently, costs $32,000 for a 12-month course of treatment. These numbers do not include the infrastructure required to deliver them safely.

The Hidden Diagnostic Tax

The drug itself is only the first line item on a very long invoice. Before your parent can even get the first drop, they need an expensive PET scan or spinal tap to prove they have amyloid plaques. Medicare covers these now, but the administrative hurdles can delay treatment for months.

Once treatment starts, the real worry is ARIA, or amyloid-related imaging abnormalities. This is the technical term for brain swelling or micro-bleeds, which occurred in about 21% of participants in the Leqembi trial. To catch this before it causes a stroke, Medicare requires regular, expensive MRI scans.

Even with Medicare covering 80% of these services, the remaining 20% co-insurance adds up fast. A single brain MRI can easily cost $1,500